Simponi

Drug Overview
Product Profiles
Simponi : Axial spondyloarthritis (axSpA)
Simponi : Rheumatoid arthritis (RA)
Simponi : Psoriatic arthritis (PsA)
Simponi : Ulcerative colitis

Figure 1: Simponi for axial spondyloarthritis – SWOT analysis
Figure 2: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 3: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 4: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Simponi for rheumatoid arthritis – SWOT analysis
Figure 6: The authors drug assessment summary of Simponi in rheumatoid arthritis
Figure 7: The authors drug assessment summary of Simponi in rheumatoid arthritis
Figure 8: Simponi for psoriatic arthritis – SWOT analysis
Figure 9: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 10: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 11: Simponi for ulcerative colitis – SWOT analysis
Figure 12: The authors drug assessment summary of Simponi for ulcerative colitis
Figure 13: The authors drug assessment summary of Simponi for ulcerative colitis

Table 1: Simponi drug profile
Table 2: Simponi pivotal trial data in axial spondyloarthritis
Table 3: Simponi Aria pivotal trial data in axial spondyloarthritis
Table 4: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 5: Simponi drug profile
Table 6: Simponi pivotal trial data in rheumatoid arthritis
Table 7: Simponi Aria pivotal trial data in rheumatoid arthritis
Table 8: Overview of the five-year efficacy and safety data for Simponi pivotal Phase III trials
Table 9: Simponi drug profile
Table 10: Simponi pivotal trial data in psoriatic arthritis
Table 11: Simponi Aria pivotal trial data in psoriatic arthritis
Table 12: Simponi drug profile
Table 13: Simponi pivotal trial data in ulcerative colitis